The cyclophosphamide market size is expected to rise owing to the rising demand for cyclophosphamide in cancer and nephrotic syndrome. Fortune Business InsightsTM has presented this information in its upcoming report titled, “Cyclophosphamide Market, 2022-2029”. Cyclophosphamide is a drug that can be taken as a tablet or as an injection. It is water-insoluble, ether and acetone sparingly soluble and easily soluble in benzene, alcohol, ethylene glycol, dioxane and chloroform. In addition, the product is a cancer-fighting chemotherapeutic treatment. It has a wide range of applications as an alkylating agent, including cancer, nephrotic syndrome, autoimmune disorders, and AL amyloidosis.

COVID-19 Impact –

Falling business confidence, growing panic among the population, and uncertainty about the future have all been impacted by the COVID-19 outbreak. Approximately half of the world’s population is restricted in their mobility, and numerous border crossings have been closed. Many governments have chosen to close non-essential firms, resulting in a sharp drop in economic activity. In many countries, unemployment has soared, further lowering the demand for products and services.

Segmentation –

On the basis of type, the market is bifurcated into low-dose and high-dose. On the basis of application, the market is fragmented into AL amyloidosis, autoimmune diseases, cancer, nephrotic syndrome, and others. On the basis of end-user, the market is divided into personal, medical, clinical, hospital, and others. Geographically, the market is classified into Latin America, Europe, North America, Asia Pacific, and the Middle East & Africa.

Report Coverage –

The report delivers an in-depth analysis of the cyclophosphamide industry. The report additionally delivers insights on the current market scenario, regional growth of the industry, key market players adopting several growth strategies in order to gain the upper hand. Furthermore, it contains information on the cumulative COVID-19 impact.

Get a Sample PDF Brochure:

www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cyclophosphamide-market-105350

Drivers & Restraints –

Rising Death Rates Due To Cancer Coupled With Healthcare Sector’s Growth To Boost The Market

By cross-linking guanine bases in DNA double-helix strands and targeting DNA directly, cyclophosphamide is used as an alkylating drug to inhibit or reduce tumor growth. It is used to treat cancers of lung cancer, the white bone and bone marrow, breast cancer, blood cell cancer, eye cancer, and others. It is used to treat a specific form of kidney disease in children with nephrotic syndrome. The rising number of deaths due to cancer diseases, together with the healthcare industry’s rapid growth, will drive up product consumption. As a result, rising demand will propel the industry forward throughout the forecast year. However, pregnant women, on the other hand, cannot consume it since it may harm their fertility. Furthermore, the product can only be consumed if it has been prescribed by doctors. These factors may hamper the cyclophosphamide market growth.

Regional Insights –

The Market in Asia Pacific to Increase at a Gradual Pace

The cyclophosphamide market share is expected to increase steadily in Asia Pacific. The tremendous rise in the healthcare industry is to blame for the increase. In addition, an increase in the number of diseases, such as blood cell cancer and lung cancer, has increased product use in this region. In North America, greater acceptance of the product in nephrotic syndrome and AL amyloidosis will drive market expansion. The increased usage of the drug in hospitals and clinics in Europe is driving the growth. Because of the product’s use in autoimmune illnesses, the Middle East & Africa are expected to see a significant increase.

Competitive Landscape –

Prominent Players to Focus on Growth Strategies

Key players in the industry are focusing on tactics like mergers and acquisitions and new product launches to sustain in the market for a longer period. Aarti Industries Limited, Chemocare, WebMD LLC, and LGM Pharma are some of the prominent players in the industry.

Industry Developments

August 2021: The U.S. Food & Drug Administration (USFDA) has given Aurobindo Pharma’s subsidiary Eugia Pharma Specialties (Eugia) a 505(b)(2) NDA approval for its cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vials. Aurobindo’s medication will be accessible in an injection preparation that is ready-to-use (RTU). The product will be released in the near future in the U.S. and will be produced at Eugia’s production facility in India.

List of Key Players in the Market:

  • Chemocare
  • WebMD LLC
  • Aarti Industries Limited
  • LGM Pharma
  • Actiza Pharmaceutical Private Limited
  • GNHIndia
  • SALVAVIDAS PHARMACEUTICAL PVT. LTD.
  • Shree Ganesh Remedies Ltd.
  • Genentech USA Inc.
  • Ocean pharmaceutical
  • Caprion Biosciences

Inquire Before Buying Reports:

www.fortunebusinessinsights.com/enquiry/queries/cyclophosphamide-market-105350

Related Posts:

Ceiling Tiles Market Data Current and Future Trends, Industry Size, Share, Revenue, Business Growth Forecast to 2027

Geogrid Market Latest Industry Size, Growth, Share, Demand, Trends, Competitive Landscape and Forecasts to 2027

Ferromanganese Market Size, Outlook, Geographical Segmentation, Business Challenges and Opportunities till 2027

Carboxymethyl Cellulose Market Size, Gross Margin, Trends, Future Demand, Analysis by Top Leading Players and Forecast till 2027

 

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Address:

Fortune Business Insights Pvt. Ltd.9th Floor, Icon Tower, Baner –

Mahalunge Road, Baner, Pune-411045,

Maharashtra, India.

Phone:

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

 Email: [email protected]

LinkedIn| Facebook |Twitter